Cellectar Biosciences

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CLRB and other ETFs, options, and stocks.

About CLRB

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. 

CEO
James V. Caruso
CEOJames V. Caruso
Employees
12
Employees12
Headquarters
Florham Park, New Jersey
HeadquartersFlorham Park, New Jersey
Founded
1996
Founded1996
Employees
12
Employees12

CLRB Key Statistics

Market cap
20.53M
Market cap20.53M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
16.14K
Average volume16.14K
High today
$3.65
High today$3.65
Low today
$3.36
Low today$3.36
Open price
$3.43
Open price$3.43
Volume
5.11K
Volume5.11K
52 Week high
$6.76
52 Week high$6.76
52 Week low
$0.337
52 Week low$0.337

CLRB Earnings

-$1.30
-$0.87
-$0.43
$0.00
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Estimated
per share
Estimated per share
Actual
Expected Nov 7, Pre-Market
ActualExpected Nov 7, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC.